Altavera 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients are increasingly reporting difficulty filling Altavera 28 Day at their local pharmacy. While no national FDA or ASHP shortage has been declared as of 2026, localized supply disruptions are creating friction for patients and generating calls and messages to prescribers. This clinical guide outlines what providers need to know: the supply landscape, substitution guidance, alternative prescribing options, and how to proactively support affected patients.

Supply Landscape: Is There a Formal Shortage?

Altavera (levonorgestrel 0.15 mg / ethinyl estradiol 0.03 mg) manufactured by Xiromed/Laboratorios Leon Farma does not appear on the FDA Drug Shortages Database or the ASHP Current Shortage List as of early 2026. The supply disruption is characterized by localized stockouts at individual pharmacy locations rather than a systemic manufacturing failure.

Contributing factors include thin generic margins resulting in limited buffer inventory, international manufacturing and distribution complexity (Spain to U.S.), and competitive substitution at the pharmacy level as pharmacies prioritize other 0.15/0.03 mg generics with stronger distribution networks.

Therapeutic Substitution: AB-Rated Equivalents

Altavera is a monophasic combination oral contraceptive. Several AB-rated generic equivalents contain the identical active ingredient profile (levonorgestrel 0.15 mg / ethinyl estradiol 0.03 mg) and can be substituted by the dispensing pharmacist when the prescription includes a generic substitution authorization. These include:

Levora (Mayne Pharma) — widely distributed; typically strong pharmacy stock

Kurvelo (Lupin Pharmaceuticals) — available at most major chains

Portia (Teva) — widely stocked; often preferred by formularies

Marlissa (Glenmark) — available option at many pharmacies

Chateal — another AB-rated equivalent

For prescriptions written with a DAW (Dispense As Written) code, the pharmacist cannot substitute. If patients are experiencing repeated access issues, consider rewriting the prescription as "LNG 0.15 mg / EE 0.03 mg — DAW 0" or writing for one of the specific therapeutically equivalent alternatives above.

Clinical Alternatives If a Different Progestin Is Needed

When a patient has a clinical reason to switch progestin class, consider these alternatives based on patient profile:

Norgestimate/EE (Sprintec, Tri-Sprintec): Most widely available COC generic; excellent supply stability; minimal androgenic effect

Drospirenone/EE (Yaz, Yasmin, Syeda): Anti-androgenic; approved for acne and PMDD; note slightly elevated VTE risk profile vs. LNG-based pills

Norethindrone/EE (Junel Fe, Lo Loestrin Fe): Low-estrogen option; good choice for patients sensitive to estrogen-related side effects

Progestin-only pill (Slynd, Opill): For patients with contraindications to estrogen (migraines with aura, smokers >35, postpartum breastfeeding)

Patient Counseling Points

When counseling patients about an Altavera supply disruption, cover these key points:

Do not abruptly discontinue pills — use backup contraception (condoms/spermicide) if doses are missed while searching for a fill

Therapeutic equivalents (Levora, Kurvelo, Portia) are bioequivalent — no additional backup contraception is needed when switching between AB-rated generics mid-cycle unless pills were missed

If switching to a different progestin class, treat as starting a new COC — advise 7 days of backup contraception (Sunday start protocol)

ACA mandates $0 cost-share for covered contraceptives — patients should not be paying out of pocket if they have qualifying coverage

Helping Patients Locate Stock

Direct patients to medfinder for providers — a service that calls pharmacies to check which ones can fill a patient's specific prescription and texts results to the patient. This reduces inbound calls to your practice and keeps patients protected. You can also see our full provider guide on how to help your patients find Altavera in stock.